135 related articles for article (PubMed ID: 37572218)
1. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase, membrane‑associated tyrosine/threonine 1 is associated with the progression of colorectal cancer.
Jeong D; Kim H; Kim D; Ban S; Oh S; Ji S; Kang D; Lee H; Ahn TS; Kim HJ; Bae SB; Lee MS; Kim CJ; Kwon HY; Baek MJ
Oncol Rep; 2018 Jun; 39(6):2829-2836. PubMed ID: 29658598
[TBL] [Abstract][Full Text] [Related]
3. PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target.
Wang J; Wang L; Chen S; Peng H; Xiao L; E Du ; Liu Y; Lin D; Wang Y; Xu Y; Yang K
Gene; 2020 Jun; 744():144608. PubMed ID: 32234541
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract][Full Text] [Related]
5. CCNE1 Amplification and PKMYT1 Inhibition Are Synthetic Lethal.
Cancer Discov; 2022 Jul; 12(7):OF12. PubMed ID: 35522064
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.
Sun QS; Luo M; Zhao HM; Sun H
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4210-4219. PubMed ID: 31173292
[TBL] [Abstract][Full Text] [Related]
7. PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.
Wang S; Liu X; Zhou T; Li J; Lin Y; Zhou A; Huang J; Zhao J; Cai J; Cai X; Huang Y; Li X
Cell Oncol (Dordr); 2023 Feb; 46(1):195-209. PubMed ID: 36350496
[TBL] [Abstract][Full Text] [Related]
8. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
[TBL] [Abstract][Full Text] [Related]
9. Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis.
Cheasley D; Pereira L; Sampurno S; Sieber O; Jorissen R; Xu H; Germann M; Yuqian Y; Ramsay RG; Malaterre J
Mol Cancer Res; 2015 Aug; 13(8):1185-96. PubMed ID: 25934694
[TBL] [Abstract][Full Text] [Related]
10. Effects of MCRS1 on proliferation, migration, invasion, and epithelial mesenchymal transition of gastric cancer cells by interacting with Pkmyt1 protein kinase.
Wang XM; Li QY; Ren LL; Liu YM; Wang TS; Mu TC; Fu S; Liu C; Xiao JY
Cell Signal; 2019 Jul; 59():171-181. PubMed ID: 30953699
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.
Zhang C; Zhu Q; Gu J; Chen S; Li Q; Ying L
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072916
[TBL] [Abstract][Full Text] [Related]
12. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y; Jiang X; Duan L; Xiong Q; Yuan Y; Liu P; Jiang L; Shen Q; Zhao S; Yang C; Chen Y
Mol Cancer; 2021 Dec; 20(1):156. PubMed ID: 34856993
[TBL] [Abstract][Full Text] [Related]
13. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma
Lu Y; Li P; Zhou Y; Zhang J
Curr Cancer Drug Targets; 2023; 23(6):496-504. PubMed ID: 36748214
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma.
Wu F; Tu C; Zhang K; Che H; Lin Q; Li Z; Zhou Q; Tang B; Yang Y; Chen M; Shao C
Biochem Biophys Res Commun; 2023 Jan; 640():173-182. PubMed ID: 36512849
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
[TBL] [Abstract][Full Text] [Related]
16. CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma.
Ma G; Yang L; Dong J; Zhang L
Curr Pharm Biotechnol; 2022; 23(9):1168-1178. PubMed ID: 34792009
[TBL] [Abstract][Full Text] [Related]
17. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
18.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
19. KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer.
Zhang X; Yin Z; Li C; Nie L; Chen K
Exp Cell Res; 2022 Aug; 417(2):113208. PubMed ID: 35580699
[TBL] [Abstract][Full Text] [Related]
20. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
Luo Q; Li X; Li J; Kong X; Zhang J; Chen L; Huang Y; Fang L
Int J Oncol; 2013 Oct; 43(4):1212-8. PubMed ID: 23900351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
